Chief, Hematology Service

Division of Hematologic Malignancies Department of Medicine
Memorial Sloan Kettering Cancer Center

The Division of Hematologic Malignancies in the Department of Medicine at Memorial Sloan Kettering Cancer Center is seeking to recruit an exceptional academic physician and leader to serve as Chief of the Hematology Service. The Division of Hematologic Malignancies is made up of 90 physicians in five services, including: Lymphoma, Leukemia, Myeloma, Benign Hematology and Adult Bone Marrow Transplantation. The Hematology Service is comprised of 5 physicians, involved in clinical care and research of benign hematological conditions in cancer patients.

The new service chief will report to the Head, Division of Hematologic Malignancies, and will have programmatic oversight and responsibility for the service and faculty. The service chief will work to shape the strategic and programmatic priorities for the service, clinical excellence, clinical operational efficiency, talent acquisition and retention, research, grant funding, professional development, mentorship and teaching. The administrative infrastructure available in the service will allow the service chief to maintain both a clinical practice and an independent research program.

At a minimum, qualified candidates should be/should have an:

- Nationally recognized clinician as well as a leader in clinical, translational, laboratory based or population science
- Extensive knowledge of the clinical care of patients with thrombosis, thrombocytopenia, and hemorrhagic disorders
- Board-eligible or board-certified in Medical Oncology
- Eligible for licensure in New York State and New Jersey

MSK has a strong commitment to enhancing the diversity of its faculty and staff. Applicants from diverse racial, ethnic, and cultural backgrounds are encouraged to apply. MSK offers competitive salaries and benefits. Interested applicants should send curriculum vitae and letter of interest to Valentina Salkow at salkowv@mskcc.org and Monchell Johnson at johnsom7@mskcc.org

For advertising information contact:
Eamon Wood
Pharmaceutical Media, Inc.
Ewood@pminy.com
(212) 904-0363
**Chief, Cellular Therapy Service**

**Division of Hematologic Malignancies**  
**Department of Medicine**  
**Memorial Sloan Kettering Cancer Center**

The Division of Hematologic Malignancies in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK) is seeking to recruit an exceptional academic physician and leader to serve as **Chief of the Cellular Therapy Service**. The Division of Hematologic Malignancies (DHM) is currently made up of over 90 physicians in five services, including: Lymphoma, Leukemia, Myeloma, Benign Hematology and Adult Bone Marrow Transplantation. In response to the ever-increasing programs for Cellular Therapy at MSK, the DHM is creating a 6th service, the Cellular Therapy Service. It will bring together two separate programs; the Cellular Therapeutics Center (CTC), currently housed in the Leukemia service, and the FDA-approved (Commercial) CAR T cell Program, currently housed in the Adult Bone Marrow Transplant Service. The Cellular Therapy Service will be responsible for the clinical and laboratory-based research, care, and program for all Immune Effector Cells, and will oversee both the investigational and FDA-approved CAR T cell program, currently completing over 100 infusions annually, with significant expected growth over the next five years.

This new service will oversee an existing Cellular Therapies program, with a large portfolio of Immune Effector Cells, overseeing both investigator and sponsor lead trials. Additionally, it will manage the Adult FDA-Approved (Commercial) CAR T cell program, which will expand to cover Hematologic Malignancy and Solid Tumor disease groups by early 2021.

The new service chief will report to the Deputy Division Head of Cellular Therapy and the Head of DHM, and will have programmatic oversight and responsibility for the service and faculty. This service will operate in a matrix reporting structure, with providers practicing in disease specific services, along with the Cellular Therapy Service. The service chief will work to shape the strategic and programmatic priorities for the service, clinical excellence, clinical operational efficiency, talent acquisition and retention, research, grant funding, professional development, mentorship and teaching. The administrative infrastructure available in the service will allow the service chief to maintain both a clinical practice and an independent research program.

At a minimum, qualified candidates should be:

- Nationally recognized clinician as well as a leader in clinical, translational, laboratory based or population science
- Extensive knowledge of the clinical care of patients with Immune Effector Cells, with experience in both Hematologic Malignancy and Solid Tumor care.
- Board-eligible or board-certified in Medical Oncology and/or Hematology
- Eligible for licensure in New York State and New Jersey

**MSK has a strong commitment to enhancing the diversity of its faculty and staff. Applicants from diverse racial, ethnic, and cultural backgrounds are encouraged to apply. MSK offers competitive salaries and benefits. Interested applicants should send curriculum vitae and letter of interest to Valentina Salkow at salkowv@mskcc.org and Monchell Johnson at johnsom7@mskcc.org**

---

**Advertise in the official journal of the American Society of Hematology**

**blood®**

For advertising information contact:

Eamon Wood  
Pharmaceutical Media, Inc.  
Ewood@pminy.com  
(212) 904-0363
**Clinician, Multiple Myeloma Program**

The Medical Oncology Hospital Medicine Program at the Dana-Farber Cancer Institute (DFCI) and Brigham and Women's Hospital (BWH) is seeking a full-time medical oncologist (MD or MD/PhD) for an academic Clinical Investigator position in our Multiple Myeloma Program. The successful candidate will participate in a very active multiple myeloma clinical practice that is fully integrated within a large and growing clinical and translational research program. Multiple opportunities exist for collaboration with basic and translational researchers in our team science-oriented program. The successful candidate is expected to take an active role in conducting clinical trials focused on hematologic malignancies. The chosen candidate will be teaching fellows and students in the inpatient setting.

The position is based in both the Department of Medical Oncology at DFCI and the Department of Medicine at the BWH and includes collaboration with other institutions affiliated with the Dana-Farber/Harvard Cancer Center and the Harvard Medical School.

The academic appointment will be at the Instructor or Assistant Professor level at Harvard Medical School and determined by the applicant's credentials. Salary and benefits will be competitive with other institutions. Applicants should have an MD or MD/PhD degree and should be with ABIM certification and be eligible for ABIM subspecialty certification in medical oncology and hematology.

**Interested candidates should submit a letter of interest by email along with their CV and the names and email addresses of three references to: Drs. Jacob Laubach and Paul Richardson, Co-Chairs, Multiple Myeloma Search Committee, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, akmouski@partners.org.**

---

**Leukemia Clinician (2 positions)**

The Department of Medical Oncology at the Dana-Farber Cancer Institute and the Department of Medicine, Brigham and Women’s Hospital, announce a search for a clinical investigator to join the Division of Leukemia. The successful candidate will participate in a very active leukemia clinical practice that is fully integrated within a large and growing clinical and translational research program. The patient population includes those with myelodysplastic syndrome and myeloproliferative neoplasms. Interest and expertise in the conduct of clinical trials with an interest in hematologic malignancies is desired. The successful candidate is expected to develop, participate, lead, and/or take an active role in the division’s multidisciplinary clinical activities.

The academic appointment will be at the Instructor or Assistant or Associate Professor level at Harvard Medical School and determined by the applicant's credentials. Salary and benefits will be competitive with other institutions. The position is based in both the Department of Medical Oncology at DFCI and the Department of Medicine at the BWH and includes collaboration with other institutions affiliated with the Dana-Farber/Harvard Cancer Center and the Harvard Medical School.

The chosen candidate will be teaching fellows and students in the inpatient setting. Applicants should have an MD or MD/PhD degree and should be with ABIM certification and be eligible for ABIM subspecialty certification in medical oncology and hematology.

**Interested candidates should submit a letter of interest by email along with their CV and the names and email addresses of three references to: Dr. Daniel J DeAngelo, Chair-Search Committee, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston MA 02215, attn: Katie Kupferberg, KKupferberg@partners.org.**